Subscribe to our mailings!

Strategy & Corporate Development

September 19, 2023

Korean Biotech on the Global Stage (Webinar Syneos Health / Treehill Partners)

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

March 20, 2025

How can Biopharma keep Trials running amidst the Funding Drought? – Expert Perspectives on Clinical Trials Arena (GlobalData)

Posted By: TreehillPartners
In: Financing & Capital Markets, Leadership & Restructuring

March 18, 2025

UK Government Looking to Drive Efficiency of Healthcare Spending – KOL Perspectives in Bioworld Medtech

Posted By: TreehillPartners
In: Uncategorized

March 5, 2025

Roundtable Discussion in The Medicine Maker

Posted By: TreehillPartners
In: Drug Development, Uncategorized

February 6, 2025

Scrip Interview with Treehill Partner Max Baumann

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

February 4, 2025

Increased focus and asking the tough questions …

Posted By: TreehillPartners
In: Strategy & Corporate Development

July 20, 2023

Biotech Value Creation (Podcast Syneos Health / Treehill Partners)

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

January 30, 2025

What can we expect the US life sciences sector to look like over the course of the next four years…

Posted By: TreehillPartners
In: Strategy & Corporate Development, Uncategorized

January 15, 2025

Europe’s CNS Scene Returns to Pharma Crosshairs – Mergermarket Interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Dealmaking, Strategy & Corporate Development

January 10, 2025

Scrip Interview With Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Strategy & Corporate Development

January 2, 2025

Trials and Capital – Biospace Podcast with Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

January 2, 2025

NHS Transformation Will be Challenging to Realize – BioWorld News Quoting Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Did you know?, Strategy & Corporate Development

May 11, 2023

New Opportunities for Value Creation: How Biotechs Can Succeed in an Increasingly Competitive Market (Webinar Syneos Health / Treehill Partners)

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

January 1, 2025

Takeovers, Trump, and Trends: How Biopharma is Likely to Shift This Year – Industry Outlook in BioXconomy featuring Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Strategy & Corporate Development

December 19, 2024

Analysis vs Beliefs and CEO Challenges – Biospace Podcast with Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

December 6, 2024

Investment Patterns 2025 – BioSpace Podcast with Treehill Partners CEO

Posted By: TreehillPartners
In: Business Development & Licensing, Financing & Capital Markets, Strategy & Corporate Development

November 27, 2024

Drug developers, investors, and other sector stakeholders preparing for a new era – Expert Opinion published on Drug Discovery World

Posted By: TreehillPartners
In: Dealmaking, Drug Development, Strategy & Corporate Development

November 15, 2024

Data Is The Underpinning of Healthcare – GEN interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development, Financing & Capital Markets, Strategy & Corporate Development

April 28, 2022

Innovation Potential in Mental Health

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.

November 7, 2024

State of the Industry – Firstword Pharma interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development

November 6, 2024

Perspectives on U.S. Election Results and Biopharma Outlook Implications

Posted By: TreehillPartners
In: Strategy & Corporate Development

October 15, 2024

BioSecure Act Ramifications – Treehill CEO feature in GlobalData article

Posted By: TreehillPartners
In: Drug Development

October 14, 2024

Disclosure of Clinical Trials – APM Health Interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development

October 1, 2024

European Immunology M&A Flares Up As Big Pharma Seeks Next Blockbuster – Ali Pashazadeh, Treehill’s CEO gives key insights for article in Mergermarket’s Snapshot series.

Posted By: TreehillPartners
In: Dealmaking

April 11, 2022

The Evolving Digital Health Landscape

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.

September 30, 2024

Biotech Course Correction – BioProcess Online podcast with Treehill Partners CEO Ali Pashazadeh

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

August 30, 2024

Long-term perspectives on new drug classes – Ali Pashazadeh, Treehill Partners CEO, quoted in Endpoints News

Posted By: TreehillPartners
In: Drug Development

July 19, 2024

Too Much Data: a Burden or a Blessing? – Clinical Trials Arena Article Quote

Posted By: TreehillPartners
In: Drug Development

July 18, 2024

Who Is Driving The Bus?

Posted By: TreehillPartners
In: Drug Development

July 15, 2024

Improving Communication – The Relationship Between Biotech And Pharma. InVivo / Citeline Commercial Podcast

Posted By: TreehillPartners
In: Business Development & Licensing, Dealmaking, Drug Development

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.